Cochrane · systematic review · CD011276
Breast surgery for metastatic breast cancer
Tosello, G, Torloni, MR, Mota, BS, et al. · Cochrane Database of Systematic Reviews · 2018 · Cochrane Library
Breast CancerAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
6
current version
GRADE rated
4
No studies
2
Included studies
NR
No studies 2 · 33.3%Ungraded 0 · 0%Very low 1 · 16.7%Low 2 · 33.3%Moderate 1 · 16.7%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Breast surgery plus systemic treatment compared to systemic treatment for metastatic breast cancer
Population: metastatic breast cancer
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival at 2 years Breast surgery plus systemic treatment vs systemic treatment | HR 0.83 [0.53, 1.31] | 2 studies · 624 participants | Very low Downgraded: risk of bias, inconsistency |
Quality of life Breast surgery plus systemic treatment vs systemic treatment | no estimate extracted | NR | No studies |
Local PFS at 2 years Breast surgery plus systemic treatment vs systemic treatment | HR 0.22 [0.08, 0.57] | 2 studies · 607 participants | Low Downgraded: risk of bias, inconsistency |
Distant PFS at 2 years Breast surgery plus systemic treatment vs systemic treatment | HR 1.42 [1.08, 1.86] | 1 study · 350 participants | Moderate Downgraded: risk of bias |
Breast cancer‐specific survival Breast surgery plus systemic treatment vs systemic treatment | no estimate extracted | NR | No studies |
Toxicity from local therapy Breast surgery plus systemic treatment vs systemic treatment | RR 0.99 [0.14, 6.9] | 1 study · 274 participants | Low Downgraded: risk of bias |